Day: April 8, 2022

SANTA ROSA, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Luther Burbank Corporation (the “Company”) (NASDAQ: LBC), the holding company for Luther Burbank Savings (the “Bank”), announced today that it will release its financial results as of and for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022. Simone Lagomarsino, President and Chief Executive Officer of Luther Burbank Corporation, and Laura Tarantino, Executive Vice President and Chief Financial Officer, will host a conference call on Wednesday, April 27, 2022 at 8:00 AM (PT) to discuss the Company’s results for the period. Analysts, investors, and the general public may listen to a discussion of the Company’s quarterly performance and a question/answer session by using the phone number or live webcast link listed below. The webcast will include...

– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy – – Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, bladder, esophagogastric junction, ovarian, head and neck, and esophageal cancers- PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 08, 2022 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a poster entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02–Eligible Patients”. “This large clinical dataset continues building the...

First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared; clinical trial to commenceLEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-12 in New Orleans, LA. “The...

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibodyIn preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 results in a reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functionsWATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today announced a presentation featuring preclinical and clinical analyses supporting...

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022. “The data we presented at this year’s AACR meeting highlight the breadth and diversity of our scientific efforts, as we continue to expand our ability to deliver off-the-shelf cell therapies with the potential to disrupt the cancer treatment landscape,” said James Trager, PhD, Chief Scientific Officer of Nkarta. “Our research activities are designed to extend the capabilities of NK cells, to lay the groundwork for further pipeline...

The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed safety profile Pharmacodynamic activity was observed at doses of 160 mg and higher The maximum tolerated dose was not reached and the dose escalation continues at 720 mg For the broad clinical AFM24 program, patients are recruited in three studies, two of which are combination studies, in 7 indicationsHEIDELBERG, Germany, April 08, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data from the dose escalation phase of the phase 1/2a study with the Company’s Innate Cell Engager (ICE®) AFM24 as monotherapy at the Annual Meeting of the American Association of Cancer Research (AACR)....

– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone – SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the results of the prespecified final progression-free survival (“PFS”) analysis and the interim overall survival (“OS”) analysis of the JUPITER-02 study (NCT03581786), a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The JUPITER-02 results are summarized in a poster presentation at the annual meeting of the American Association for Cancer Research (“AACR”). In...

– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – – IND or equivalent filings planned for two new product candidates in 2022, including masked anti-CD137 antibody with Fc engineering and masked anti-CD47 antibody, designed to enhance both safety and efficacy – SAN DIEGO and SUZHOU, China, April 08, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates. Data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana from April 8-13, 2022. Posters are available in...

– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 – Findings also identify highest frequency of TSC1 alterations in bladder, kidney, and lung squamous cell cancers, while TSC2 alterations have the highest frequency in hepatobiliary, ovarian, and soft tissue sarcomas LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of a poster (#5799) at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 8-13, 2022 in New Orleans, LA. The research that was presented...